Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 138-145

  Pan, Guoyu ^a   Winter, Tate N ^a   Roberts, John C ^a   Fairbanks, Carolyn A ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Agmatine; BCRP; OCT2; OCT3; Polyamine transporter; Transporter regulation

Indexed keywords

AGMATINE; CHOLINE; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PRAZOSIN; PROTEIN BCRP1; UNCLASSIFIED DRUG;

ARTICLE; CATION TRANSPORT; CELL TYPE; DRUG ACCUMULATION; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY TUBULE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; DOGS; HUMANS; ION TRANSPORT; MICE; MODELS, BIOLOGICAL; ORGANIC CATION TRANSPORT PROTEINS; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSFECTION;

EID: 76249105611     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900177r     Document Type: Article

References (30)

1. Mochizuki, T.; Satsu, H; Shimizu, M. Tumor necrosis factor alpha stimulates taurine uptake and transporter gene expression in human intestinal Caco-2 cells. FEBS Lett. 2002, 517, 92-96.
2. Urakami, Y.; Okuda, M.; Saito, H.; Inui, K. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett. 2000, 473, 173-176.
3. Hoffmann, K.; Loscher, W. Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia 2007, 48 (4), 631-645.
4. Raggers, R. J.; Vogels, I.; van Meer, G. Upregulation of the expression of endogenous Mdr1 P-glycoprotein enhances lipid translocation in MDCK cells transfected with human MRP2. Histochem. Cell Biol. 2002, 117 (2), 181-185.
5. Jonker, J. W.; Smit, J. W.; Brinkhuis, R. F.; Maliepaard, M.; Beijnen, J. H.; Schellens, J. H.; Schinkel, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 2000, 92, 1651-1656.
6. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402-408.
7. Rudolph, C.; Adam, G.; Simm, A. Determination of copy number of c-Myc protein per cell by quantitative Western blotting. Anal. Biochem. 1999, 269, 66-71.
8. Reis, D. J.; Regunathan, S. Is agmatine a novel neurotransmitter in brain. Trends Pharmacol. Sci. 2000, 21 (5), 187-193.
9. Qiu, W. W.; Zheng, R. Y. Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine. Neurosci. Bull. 2006, 22 (3), 187-191.
10. Wang, W. P.; Iyo, A. H.; Miguel-Hidalgo, J.; Regunathan, S.; Zhu, M. Y. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res. 2006, 1084, 210-216.
11. Wang, J. F.; Su, R. B.; Wu, N.; Xu, B.; Lu, X. Q.; Liu, Y.; Li, J. Inhibitory effect of agmatine on proliferation of tumor cells by modulation of polyamine metabolism. Acta Pharmacol. Sin. 2005, 26, 616-622.
12. Isome, M.; Lortie, M. J.; Murakami, Y.; Parisi, E.; Matsufuji, S.; Satriano, J. The antiproliferative effects of agmatine correlates with the rate of cellular proliferation. Am. J. Physiol. Cell Physiol. 2007, 293, C705-C711.
13. Grundemann, D.; Hahne, C.; Berkels, R.; Schomig, E. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (OCT3) and organic cation transporter 2 (OCT2). J. Pharmacol. Exp. Ther. 2003, 304, 810-817.
14. Satriano, J.; Isome, M.; Casero, R. A., Jr.; Thomson, S. C.; Blantz, R. C. Polyamine transport system mediates agmatine transport in mammalian cells. Am. J. Physiol. 2001, 281, C329-C334.
15. Aziz, S. M.; Worthen, D. R.; Yatin, M.; Ain, K. B.; Crooks, P. A. A unique interaction between polyamine and multidrug resistance (P-glycoprotein) transporters in cultured Chinese hamster ovary cells transfected with mouse mdr-1 gene. Biochem. Pharmacol. 1998, 56, 181-187.
16. Park, C. S.; Cho, K.; Bae, D. R.; Joo, N. E.; Kim, H. H.; Mabasa, L.; Fowler, A. W. Methyl-donor nutrients inhibit breast cancer cell growth. In Vitro Cell. Dev. Biol.: Anim. 2008, 44 (7), 268-272.
17. Sweet, D. H.; Miller, D. S.; Pritchard, J. B. Basolateral localization of organic cation transporter 2 in intact renal proximal tubules. Am. J. Physiol. 2002, 279, F826-F834.
18. Shu, Y.; Bello, C. L.; Mangravite, L. M.; Feng, B.; Giacomini, K. M. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J. Pharmacol. Exp. Ther. 2001, 299, 392-398.
19. Milovic, V.; Stein, J.; Piiper, A.; Gerhard, R.; Zeuzem, S.; Caspary, W. F. Characterization of putrescine transport across the intestinal epithelium: study using isolated brush border and basolateral membrane vesicles of the enterocyte. Eur. J. Clin. Invest. 1995, 2, 97-105.
20. Ifergan, I.; Assaraf, Y. G. Molecular mechanims of adaption to folate deficiency. Vitam. Horm. 2008, 79, 99-143.
21. Sweet, D. H.; Miller, D. S.; Pritchard, J. B. Ventricular choline transport, a role for organic cation transporter 2 expressed in choroid plexus. J. Biol. Chem. 2001, 276, 41611-41619.
22. Eliyahu, G.; Kreizman, T.; Degani, H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer, 2007, 120, 1721-1730.
23. Katz-Brull, R.; Seger, D.; Rivenson-Segal, D.; Rushkin, E.; Degani, H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002, 62, 1966-1970.
24. Pan, G.; Elmquist, W. F. Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol. Pharmaceutics 2007, 4, 475-483.
25. Robey, R. W.; Honjo, Y.; Morisaki, K.; Nadjem, T. A.; Runge, S.; Risbood, M.; Poruchynsky, M. S.; Bates, S. E. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 2003, 89, 1971-1978.
26. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670.
27. Pavek, P.; Merino, G.; Wagenaar, E.; Bolscher, E.; Novotna, M.; Jonker, J. W.; Schinkel, A. H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 2005, 2 (1), 144-152.
28. Barendt, W. M.; Wright, S. H. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J. Biol. Chem. 2002, 277 (25), 22491-22496.
29. Katz-Brull, R.; Lavin, P. T.; Lenkinski, R. E. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 2002, 94 (16), 1197-1203.
30. Cullinane, C.; Dorow, D. S.; Kansara, M.; Conus, N.; Binns, D.; Hicks, R. J.; Ashman, L. K.; McArthur, G. A.; Thomas, D. M. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res. 2005, 65, 9633-9636.